AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 139565
Drug: Spectinomycin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spectinomycin (2 or 4 g once)
Trial: 139565
Drug: Tetracycline (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline (9 g orally for four days)
Trial: 11436953
Drug: Sertraline treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline treatment for 14 weeks
Trial: 11436953
Drug: Sertraline group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline group
Trial: 29702133
Drug: Bio-K+ probiotic
RxNorm normalized name: Bio-Kool
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bio-K+ probiotic formulation (Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, Lactobacillus rhamnosus CLR2)
Trial: 24356624
Drug: Axitinib (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axitinib (5 mg twice daily) with paclitaxel (200 mg/m2 Q3W)/carboplatin (AUC 6 mg min/ml Q3W)
Trial: 24356624
Drug: Bevacizumab (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (15 mg/kg every 3 weeks) with paclitaxel (200 mg/m2 Q3W)/carboplatin (AUC 6 mg min/ml Q3W)
Trial: 22223702
Drug: Myo-inositol (MYO)
RxNorm normalized name: myo-inositol
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Myo-inositol (MYO) 1200 mg/day for 12 weeks
Trial: 21073267
Drug: Nurse-led patient
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse-led patient education programme and care plan (including lifestyle changes, home-based exercise training, weekly nurse consultations)
Trial: 17714542
Drug: Stimulation of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulation of sucking and swallowing (one daily session of stimulation according to Vojta)
Trial: 2782247
Drug: Controlled-release isosorbide-5-mononitrate
RxNorm normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Controlled-release isosorbide-5-mononitrate (ISMN) 60 mg daily
Trial: 2782247
Drug: Immediate-release isosorbide
RxNorm normalized name: isosorbide Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release isosorbide dinitrate (ISDN) 30 mg, 4 times daily
Trial: 935199
Drug: Propranolol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (40 mg, 6 doses, given at 6 hour intervals)
Trial: 28213743
Drug: CER-001 (0.25-45.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CER-001 (0.25-45.0 mg/kg)
Trial: 28213743
Drug: CER-001 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CER-001 (2 mg/kg and above)
Trial: 26531066
Drug: Accelerated, multiple,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated, multiple, double-dose HB vaccine (40 μg) administered at 0, 1, and 3 weeks before chemotherapy and additional three double doses post chemotherapy.
Trial: 26531066
Drug: Conventional HB
RxNorm normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional HB vaccine (20 μg) administered at 0, 1, and 6 months.
Trial: 23208320
Drug: Mirabegron 100
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirabegron 100 mg single oral dose
Trial: 16532442
Drug: Radiofrequency treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiofrequency treatment (Thermage ThermaCool TC) delivered at 63.5 setting with medium-fast 1.5 cm2 tip over injected sites.
Trial: 16532442
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with augmentation materials alone (no RF treatment).
Trial: 12435653
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy (N = 33)
Trial: 12435653
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (N = 34)
Trial: 2036245
Drug: levamisole (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levamisole (2.5 mg/kg on two consecutive days every week except on chemotherapy days)
Trial: 12816220
Drug: APC tonsillectomy
RxNorm normalized name: Recombinant human activated protein C (rH-APC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APC tonsillectomy (treatment B)
Trial: 12816220
Drug: Conventional tonsillectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional tonsillectomy (treatment A)
Trial: 9145871
Drug: Artemisinin capsules
RxNorm normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisinin capsules (500 mg) administered with food
Trial: 9145871
Drug: Artemisinin capsules
RxNorm normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisinin capsules (500 mg) administered without food
Trial: 7698137
Drug: k-strophanthidin (0.0035
FDA approved: no
EMA approved: no
PMDA approved: no
Description: k-strophanthidin (0.0035 mg.kg-1 for 10 min)
Trial: 2455126
Drug: Diltiazem (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (20 mg/l in Eurocollin's solution, bolus injection of 0.28 mg/kg, continuous infusion of 0.002 mg/min/kg for 2 days, then 60 mg orally twice daily)
Trial: 2455126
Drug: Diltiazem treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem treatment group
Trial: 29699757
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment period
Trial: 27790252
Drug: 6% sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% sodium hypochlorite (NaOCl) irrigation (single session treatment)
Trial: 25436073
Drug: Alternate Sequential
RxNorm normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternate Sequential Compression Device (ASCD)
Trial: 25436073
Drug: Simultaneous Sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous Sequential Compression Device (SSCD)
Trial: 23415342
Drug: Online Evidence-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online Evidence-based Medicine course (immediate intervention group, n=58)
Trial: 20100336
Drug: Direct endomyocardial
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct endomyocardial autologous bone marrow cell injection
Trial: 16368814
Drug: Nefopam 20
RxNorm normalized name: nefopam 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam 20 mg intraoperatively
Trial: 16368814
Drug: Large-dose remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large-dose remifentanil (Group L: 8 ng/mL)
Trial: 16368814
Drug: Small-dose remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small-dose remifentanil (Group S: 3 ng/mL)
Trial: 7715291
Drug: Fluorouracil and
RxNorm normalized name: Fluorouracil and salicylic acid only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorouracil and folinic acid (370-400 mg/m2 plus 200 mg/m2 daily for 5 days, every 28 days for 6 cycles)
Trial: 2707458
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (CC) (100 mg) by mouth on cycle days 5 to 9
Trial: 2707458
Drug: Treatment-independent pregnancies
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-independent pregnancies (before treatment or more than 1 month after therapy)
Trial: 7343127
Drug: Mass drug
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass drug administration (chemoprophylaxis) given every 15 days
Trial: 28104830
Drug: High flow
RxNorm normalized name: Blood Set High Flow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High flow oxygen therapy (HFOT)
Trial: 14693596
Drug: Rocuronium 0.60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.60 mg/kg
Trial: 7714113
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion during euglycemic conditions
Trial: 7714113
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion during hyperglycemic conditions
Trial: 7714113
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion during hyperglycemic vs euglycemic conditions
Trial: 22818896
Drug: Intravitreal injections
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injections of bevacizumab every 6 weeks for the first 3 injections followed by injections every 6 weeks (regimen A, n = 91)
Trial: 22818896
Drug: Intravitreal injections
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injections of bevacizumab every 12 weeks (regimen B, n = 94)
Trial: 19206044
Drug: Orbital floor
RxNorm normalized name: barbital
DrugBank: Barbital (DB01483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orbital floor triamcinolone acetonide injection
Trial: 17189654
Drug: Home telemonitoring
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home telemonitoring of vital signs and respiration (weekly monitoring of 12 parameters, monthly 24-hour recording)
Trial: 12040968
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg ambroxol hydrochloride
Trial: 12040968
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg ambroxol hydrochloride
Trial: 2533410
Drug: Sodium metabisulphite
RxNorm normalized name: Sodium metabisulphite
DrugBank: Sodium metabisulfite (DB15842)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium metabisulphite aerosol (0.3 to 160 mg/ml)
Trial: 2533410
Drug: Sodium metabisulphite
RxNorm normalized name: Sodium metabisulphite
DrugBank: Sodium metabisulfite (DB15842)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium metabisulphite aerosol (PD20 dose)
Trial: 2533410
Drug: Sodium metabisulphite
RxNorm normalized name: Sodium metabisulphite
DrugBank: Sodium metabisulfite (DB15842)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium metabisulphite (second inhalation of same PD20 dose)
Trial: 727428
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg of domperidone
Trial: 24750327
Drug: P/R +
RxNorm normalized name: Piperacillin/Tazobactam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P/R + V (Peg‐IFNα2a and Ribavirin + E1E2MF59 vaccine)
Trial: 22134600
Drug: CIDR protocol
RxNorm normalized name: Eazi-Breed CIDR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIDR protocol (controlled intravaginal progesterone releasing insert, 1.38 g of progesterone)
Trial: 22134600
Drug: PGF2alpha analogue
RxNorm normalized name: PGF2alpha THAM
DrugBank: Dinoprost tromethamine (DB01160)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGF2alpha analogue cloprostenol (0.5 mg per animal i.m.)
Trial: 19554089
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E and allopurinol treatment for 3-5 days before surgery
Trial: 17824352
Drug: Systematic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systematic treatment of depression in elderly individuals
Trial: 9626221
Drug: Radiotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy and 1-(2-chloroethyl)-3(2,6 dioxo-l-piperidyl)-1-nitrosource a (PCNU)
Trial: 3610511
Drug: Benzydamine hydrochloride
RxNorm normalized name: benzydamine hydrochloride
DrugBank: Benzydamine (DB09084)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzydamine hydrochloride pump spray
Trial: 31418814
Drug: aP-containing vaccines
RxNorm normalized name: AP-101
DrugBank: AP-101 (DB17947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aP-containing vaccines
Trial: 31418814
Drug: wP-containing vaccines
RxNorm normalized name: WP Thyroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: wP-containing vaccines (control group)
Trial: 31418814
Drug: wP-containing vaccines
RxNorm normalized name: WP Thyroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: wP-containing vaccines
Trial: 22916805
Drug: Pulse-based diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulse-based diet (two servings daily of beans, chickpeas, peas or lentils; about 150 g/d dry weight)
Trial: 20165821
Drug: Metoclopramide injections
RxNorm normalized name: metoclopramide Injection
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoclopramide injections
Trial: 20165821
Drug: Radiation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation treatment (RT)
Trial: 18701691
Drug: Paired associative
RxNorm normalized name: HEPATITIS ASSOCIATED ANTIBODY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paired associative stimulation (PAS) at 8:00 P.M. after oral hydrocortisone (24 mg)
Trial: 18701691
Drug: Oral hydrocortisone
RxNorm normalized name: hydrocortisone Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hydrocortisone (24 mg)
Trial: 10951799
Drug: Fentanyl (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (50 ug) added to 20 ml of 0.125% bupivacaine
Trial: 10951799
Drug: Ketamine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (50 mg) added to 20 ml of 0.125% bupivacaine
Trial: 7740948
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of cephalosporins 20 minutes before tourniquet inflation
Trial: 28975432
Drug: Fortified milk
RxNorm normalized name: Fortified milk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fortified milk (1200 mg calcium, 96 mg magnesium, 2.4 mg zinc, 15 μg vitamin D, 4 g FOS-inulin per day)
Trial: 28975432
Drug: Regular milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular milk (428 mg calcium per day)
Trial: 26374911
Drug: hIVIG (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hIVIG (0.25 g/kg)
Trial: 25934631
Drug: Dietary nitrate
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary nitrate supplementation as beetroot juice (4.8 mmol twice a day for 3 days)
Trial: 23632980
Drug: Carotid endarterectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carotid endarterectomy and appropriate medication
Trial: 16787802
Drug: Multiple-dose activated
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-dose activated charcoal (G1)
Trial: 16787802
Drug: Simple dose
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple dose of 1 g/kg activated charcoal (G2)
Trial: 10741624
Drug: Probenecid (1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probenecid (1,500 mg)
Trial: 7756094
Drug: Feedback-controlled infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Feedback-controlled infusions of omeprazole (target pH 5, dose range 0-12 mg h-1) with an initial bolus of 80 mg
Trial: 7756094
Drug: Fixed-dose infusions
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose infusions of omeprazole (8 mg h-1) with an initial bolus of 80 mg
Trial: 7756094
Drug: Initial bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial bolus of 40 mg omeprazole followed by feedback-controlled infusions
Trial: 7756094
Drug: Initial bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial bolus of 80 mg omeprazole followed by feedback-controlled infusions
Trial: 6155203
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of bleomycin and adriamycin (chemotherapy)
Trial: 6155203
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of bleomycin and adriamycin with radiation (3600-4000 rad)
Trial: 30877271
Drug: Citalopram infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram infusion in MDD patients
Trial: 30877271
Drug: Citalopram infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram infusion in healthy controls
Trial: 30877271
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion in MDD patients
Trial: 30877271
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion in healthy controls
Trial: 28540894
Drug: Hydrochlorothiazide (HCTZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ) 1 mg/kg/day for 3 months
Trial: 21729686
Drug: AEG35156 (650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AEG35156 (650 mg) in combination with high-dose cytarabine and idarubicin
Trial: 21729686
Drug: High-dose cytarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cytarabine and idarubicin alone
Trial: 19192840
Drug: 15% carbamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15% carbamide peroxide gel (bleaching group)
Trial: 16983592
Drug: Neoadjuvant 8-week
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Neoadjuvant 8-week dose-dense doxorubicin plus docetaxel
Trial: 12734908
Drug: Sodium oxybate
RxNorm normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium oxybate (6.0 g/day)
Trial: 11061657
Drug: Standard recommendation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard recommendation of 200 mg daily during the first 2 weeks (n = 166)
Trial: 11061657
Drug: Prednisone 50
RxNorm normalized name: prednisone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone 50 mg every other day during the first 2 weeks (n = 93)
Trial: 11061657
Drug: Slowly escalating
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slowly escalating dose starting with 100 mg daily (n = 107)
Trial: 11061657
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of prednisone and slowly escalating dose (n = 103)
Trial: 11061657
Drug: New approaches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New approaches (including prednisone and slowly escalating dose)
Trial: 9077371
Drug: IGF‐I [8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGF‐I [8 micrograms kg‐1 h‐1] by continuous subcutaneous infusion
Trial: 9077371
Drug: GH (6
RxNorm normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GH (6 U. twice daily s.c.) for 5 days
Trial: 26290867
Drug: LC n‐3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LC n‐3 PUFAs (2.52 g/day)
Trial: 18555827
Drug: Full-dose almonds
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose almonds (73 +/- 3 g/d)
Trial: 18424600
Drug: Half-dose almonds
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose almonds plus half-dose muffins
Trial: 8780944
Drug: Thymostimulin (TP1)
RxNorm normalized name: thymostimulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymostimulin (TP1) at dosages of 0.5 mg/kg, 1.0 mg/kg, and 2.0 mg/kg body weight
Trial: 1623900
Drug: dexfenfluramine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dexfenfluramine (30 mg daily)
Trial: 6597721
Drug: Indometacin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indometacin (3 X 50 mg daily)
Trial: 6597721
Drug: Carprofen (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carprofen (2 X 150 mg daily)
Trial: 6597721
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 X daily)
Trial: 12470198
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E supplementation (400 mg/day for 6 weeks)
Trial: 2782269
Drug: Propranolol +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol + Nifedipine (10 or 20 mg every 8 hours)
Trial: 2782269
Drug: Propranolol +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol + Diltiazem (60 or 120 mg every 8 hours)
Trial: 23319447
Drug: High-fat diet
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fat diet (15.4 g of fat)
Trial: 23319447
Drug: Low-fat diet
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat diet (4.0 g of fat)
Trial: 21422304
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment to the left temporoparietal junction for 2 weeks
Trial: 21422304
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of active rTMS vs sham treatment
Trial: 8133561
Drug: Rice-based ORS
RxNorm normalized name: Rice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rice-based ORS (50 g/l)